BIOMAT Database Logo BIOMAT Database Logo

The effect of oxitropium bromide on neurokinin A-induced bronchoconstriction in asthmatic subjects. 1988

G Joos, and R Pauwels, and M Van Der Straeten
University Hospital, Department of Respiratory Diseases, Ghent, Belgium.

In some animal species substance P and neurokinin A (NKA) cause bronchoconstriction by the release of acetylcholine from postganglionic cholinergic nerve endings. The aim of the present study was to investigate the effect of an anticholinergic drug, oxitropium bromide, on bronchoprovocation with NKA in asthmatics. Eleven mild asthmatics (mean % predicted FEV1 85.5) received on 2 separate days, double blind, in a randomised order, 400 mcg oxitropium bromide or placebo, 90 min before challenge with NKA. NKA was inhaled at 3 concentrations (10(-4), 3.10(-4) and 10(-3) M). Specific airways conductance (sGaw) and forced expiratory volume in 1 s (FEV1) were used as parameters of airway calibre. Compared to the placebo-aerosol, oxitropium bromide caused a significant increase in sGaw and FEV1. On the placebo-treatment day, NKA caused a concentration-dependent decrease in sGaw and FEV1. The percentage changes in sGaw and FEV1 on the oxitropium day were not statistically different from those occurring on the placebo day. We conclude that oxitropium bromide caused a significant bronchodilation but offered no significant protection against NKA-induced bronchoconstriction in mild asthmatic subjects.

UI MeSH Term Description Entries
D008297 Male Males
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D012602 Scopolamine Derivatives Analogs or derivatives of scopolamine. Scopolamines,Derivatives, Scopolamine
D015288 Neurokinin A A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI. Substance K,Neurokinin alpha,Neuromedin L
D016084 Bronchoconstriction Narrowing of the caliber of the BRONCHI, physiologically or as a result of pharmacological intervention. Bronchial Constriction,Bronchial Constrictions,Bronchoconstrictions,Constriction, Bronchial,Constrictions, Bronchial

Related Publications

G Joos, and R Pauwels, and M Van Der Straeten
Effect of nicardipine on acetylcholine-induced bronchoconstriction in asthmatic subjects.
August 1988, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
G Joos, and R Pauwels, and M Van Der Straeten
Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects.
April 1989, Annals of allergy,
G Joos, and R Pauwels, and M Van Der Straeten
A method for measuring the effects of anticholinergics on histamine-induced bronchoconstriction in normal subjects. Oxitropium bromide provides dose-dependent protection.
April 1994, Respiratory medicine,
G Joos, and R Pauwels, and M Van Der Straeten
Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects.
May 1994, American journal of respiratory and critical care medicine,
G Joos, and R Pauwels, and M Van Der Straeten
Inhibition of methoxamine-induced bronchoconstriction by ipratropium bromide and disodium cromoglycate in asthmatic subjects.
July 1985, British journal of clinical pharmacology,
G Joos, and R Pauwels, and M Van Der Straeten
Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects.
November 1996, Chest,
G Joos, and R Pauwels, and M Van Der Straeten
Comparison of the bronchodilating effect of oxitropium bromide and fenoterol in asthmatic children.
August 1994, European journal of pediatrics,
G Joos, and R Pauwels, and M Van Der Straeten
The effect of oral terfenadine on neurokinin-A-induced bronchoconstriction.
May 1993, The Journal of allergy and clinical immunology,
G Joos, and R Pauwels, and M Van Der Straeten
The effect of inhaled fenoterol and ipratropium bromide on propranolol induced bronchoconstriction in the asthmatic airways.
September 1990, Clinical and experimental pharmacology & physiology,
G Joos, and R Pauwels, and M Van Der Straeten
Single-dose effect of astemizole on bronchoconstriction induced by histamine in asthmatic subjects.
May 1992, Chest,
Copied contents to your clipboard!